(NASDAQ: GANX) Gain Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.39%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Gain Therapeutics's revenue in 2024 is $0.On average, 2 Wall Street analysts forecast GANX's revenue for 2024 to be $7,220,792, with the lowest GANX revenue forecast at $1,805,198, and the highest GANX revenue forecast at $12,636,385. On average, 3 Wall Street analysts forecast GANX's revenue for 2025 to be $5,289,230, with the lowest GANX revenue forecast at $3,249,356, and the highest GANX revenue forecast at $7,220,792.
In 2026, GANX is forecast to generate $4,151,955 in revenue, with the lowest revenue forecast at $4,151,955 and the highest revenue forecast at $4,151,955.